Evidence map›Paper›PMID 35377902›Full record

ArticlePloS one2022

Olfactory identification disorders due to Alzheimer's disease: A new test from France to Quebec.

Magali Payne, Valeria Manera, Philippe Robert, Clair Vandersteen, Olivier Beauchet, Kevin Galery, Guillaume Sacco, Roxane Fabre, Auriane Gros

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. The first quick olfactory test specific for Alzheimer's disease and French culture.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024
    Article
  2. A Perspective: Challenges in Dementia Research.Medicina (Kaunas, Lithuania) · 2022
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Magali PayneCoBteK lab (Cognition Behavior and Technology), Université Cote d'Azur, Nice, France.ORCID 0000-0002-6257-2587
Valeria ManeraCoBteK lab (Cognition Behavior and Technology), Université Cote d'Azur, Nice, France.
Philippe RobertCoBteK lab (Cognition Behavior and Technology), Université Cote d'Azur, Nice, France.
Clair VandersteenInstitut Universitaire de la Face et du Cou, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France.
Olivier BeauchetResearch Center of the Institut Universitaire en Gériatrie de Montréal, University of Montreal, Montreal, Canada.
Kevin GaleryResearch Center of the Institut Universitaire en Gériatrie de Montréal, University of Montreal, Montreal, Canada.
Guillaume SaccoCoBteK lab (Cognition Behavior and Technology), Université Cote d'Azur, Nice, France.ORCID 0000-0002-6881-1649
Roxane FabreCoBteK lab (Cognition Behavior and Technology), Université Cote d'Azur, Nice, France.ORCID 0000-0001-5670-1322
Auriane GrosCoBteK lab (Cognition Behavior and Technology), Université Cote d'Azur, Nice, France.
Université Côte d'Azur · FRCognition Behaviour Technology · FRInstitut Universitaire de Gériatrie de Montréal · CANanyang Technological University · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Olfactory identification disorder is regarded as an early marker of Alzheimer's disease (AD) and of similar diagnostic significance of biological or cognitive markers. Premature damage of the entorhinal olfactory cortex, the hippocampus and the orbitofrontal cortex characterize AD and suggest a specific impairment of olfactory identification. The use of psychophysical olfactory identification tests in clinical diagnostic practice is therefore strongly recommended, but not required. As these widespread tests are rarely used, an innovative test, adapted to this target group has been developed. It has been used and validated in a routine care protocol at different Memory Centers in France and in Quebec, Canada. A total of 157 participants were recruited: including 63 Alzheimer's patients and 94 healthy controls. The test was composed of 14 odorants diluted into 4 different concentrations. A computer interface generated randomization of 6 odors per participant and the automatic calculation of identification scores, of perceptual thresholds and of composite scores. All participants underwent a Mini Mental Scale Examination within the previous three months or on the same day of the olfactory test. The Alzheimer's patients had a score between 20 and 30 and healthy controls participants had a score above 28 without any loss of points on recalled items. The results show that our olfactory identification test is able to significantly differentiate Alzheimer's patients from healthy controls (p < 0.001), and to distinguish the French population tested from the Quebec population (p < 0.001). This study highlights an olfactory identification disorder as a target for early diagnosis of AD. Its cultural qualities make it a potential candidate for differentiated calibration between France and Quebec.

Indexed as

Alzheimer DiseaseOlfaction DisordersFranceHumansNeuropsychological TestsQuebecSmell

Identifiers

PMID35377902
PMCPMC8979441
OpenAlexW4226202553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.